文献速递痛风与晶体性关节病

1990-2017年全球195个国家痛风患病率、发病率及伤残损失寿命年:GBD 2017系统分析

Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017.
PubMed 文献 · Arthritis Rheumatol · 2020-09-10

基于GBD 2017研究,系统分析195个国家1990-2017年痛风点患病率、年发病率及伤残损失寿命年(YLD)的水平与趋势,并按年龄、性别和社会人口指数(SDI)分层。

要点

  • 高BMI和肾功能受损分别贡献痛风YLD的32.4%和15.3%,男性负担更高。
  • 痛风负担在发达地区最高,2017年年龄标化点患病率前三为新西兰、澳大利亚和美国。

核心结论

  • 1990至2017年全球痛风负担总体上升,点患病率、年发病率和YLD均增加,且存在国家与地区间差异。
  • 除改善临床管理外,社区预防和健康促进对高危人群(如中年男性)至关重要。

研究设计与样本

  • 数据提取自全球疾病负担(GBD)2017研究,由GBD团队联合全球研究者进行系统综述和疾病建模分析。
  • 报告1990至2017年全球、区域和国家层面的点患病率、年发病率及YLD的计数和每10万人口年龄标化率,含95%不确定性区间(95% UI)。

主要发现

  • 2017年全球年龄标化点患病率为510.6/10万(95% UI 455.6至570.3),年发病率为91.8/10万(95% UI 81.3至104.1),较1990年分别增加7.2%(95% UI 6.4%至8.1%)和5.5%(95% UI 4.8%至6.3%)。
  • 2017年年龄标化YLD率为15.9/10万(95% UI 10.7至21.8),较1990年增加7.2%(95% UI 5.9%至8.6%)。
  • 2017年男性痛风点患病率高于女性,老年组患病率更高,且男女患病率均随年龄增长而升高。
  • 2017年年龄标化点患病率最高的三国为新西兰(1394.0/10万,95% UI 1290.1至1500.9)、澳大利亚(1171.4/10万,95% UI 1038.1至1322.9)和美国(996.0/10万,95% UI 923.1至1076.8)。

关键数值与推荐

  • 2017年全球高体重指数和肾功能受损分别归因于32.4%(95% UI 18.7%至49.2%)和15.3%(95% UI 13.5%至17.1%)的痛风YLD。
  • 1990至2017年年龄标化点患病率增幅最大的国家为美国(34.7%,95% UI 27.7%至43.1%)、加拿大(28.5%,95% UI 21.9%至35.4%)和阿曼(28.0%,95% UI 21.5%至34.8%)。

临床怎么用

  • 风湿免疫科应关注痛风全球负担上升趋势,重视中年男性等高危人群的早期识别与干预。
  • 临床管理之外,应结合高体重指数和肾功能受损等可归因风险因素开展社区预防和健康促进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the levels and trends of point prevalence, annual incidence, and years lived with disability (YLD) for gout and its attributable risk factors in 195 countries and territories from 1990 to 2017 according to age, sex, and Sociodemographic Index (SDI; a composite of sociodemographic factors). METHODS: Data were extracted from the Global Burden of Disease (GBD) 2017 study. A comprehensive systematic review of databases and the disease-modeled analysis were performed by the GBD team at the Institute for Health Metrics and Evaluation, in collaboration with researchers and experts worldwide, to provide estimates at global, regional, and national levels during 1990 and 2017. Counts and age-standardized rates per 100,000 population, along with 95% uncertainty intervals (95% UIs), were reported for point prevalence, annual incidence, and YLD. RESULTS: Globally, there were ~41.2 million (95% UI 36.7 million, 46.1 million) prevalent cases of gout, with 7.4 million incident cases per year (95% UI 6.6 million, 8.5 million) and almost 1.3 million YLD (95% UI 0.87 million, 1.8 million) in 2017. The global age-standardized point prevalence estimates and annual incidence rates in 2017 were 510.6 (95% UI 455.6, 570.3) and 91.8 (95% UI 81.3, 104.1) cases per 100,000 population, respectively, an increase of 7.2% (95% UI 6.4%, 8.1%) and 5.5% (95% UI 4.8%, 6.3%) from 1990. The corresponding age-standardized YLD rate was 15.9 (95% UI 10.7, 21.8) cases per 100,000 persons, a 7.2% increase (95% UI 5.9%, 8.6%) from 1990. In 2017, the global point prevalence estimates for gout were higher in males, and higher prevalence was seen in older age groups and increased with age for both males and females. The burden of gout was generally highest in developed regions and countries. The 3 countries with the highest age-standardized point prevalence estimates of gout in 2017 were New Zealand (1,394.0 cases [95% UI 1,290.1, 1,500.9]), Australia (1,171.4 cases [95% UI 1,038.1, 1,322.9]), and the US (996.0 cases [95% UI 923.1, 1,076.8]). The countries with the highest increases in age-standardized point prevalence estimates of gout from 1990 to 2017 were the US (34.7% [95% UI 27.7%, 43.1%]), Canada (28.5% [95% UI 21.9%, 35.4%]), and Oman (28.0% [95% UI 21.5%, 34.8%]). Globally, high body mass index and impaired kidney function accounted for 32.4% (95% UI 18.7%, 49.2%) and 15.3% (95% UI 13.5%, 17.1%), respectively, of YLD due to gout in the 2017 estimates. The YLD attributable to these risk factors were higher in males. CONCLUSION: The burden of gout increased across the world from 1990 to 2017, with variations in point prevalence, annual incidence, and YLD between countries and territories. Besides improving the clinical management of disease, prevention and health promotion in communities to provide basic knowledge of the disease, risk factors, consequences, and effective treatment options (tailoring to high-risk groups such as the middle-aged male population) are crucial to avoid disease onset and hence to decrease the global disease burden.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Safiri S, Kolahi AA, Cross M, et al. Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol. 2020. PMID: 32755051. doi:10.1002/art.41404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。